PMID- 37258427
OWN - NLM
STAT- MEDLINE
DCOM- 20230602
LR  - 20230602
IS  - 0219-6352 (Print)
IS  - 0219-6352 (Linking)
VI  - 22
IP  - 3
DP  - 2023 May 8
TI  - Apigenin Alleviates Allodynia and Hyperalgesia in a Mouse Model of 
      Chemotherapy-Induced Peripheral Neuropathy via Regulating Microglia Activation 
      and Polarization.
PG  - 64
LID - 10.31083/j.jin2203064 [doi]
AB  - BACKGROUND: Apigenin has been reported to exhibit anti-inflammatory and 
      anti-oxidative activities. This study aimed to investigate the protective role of 
      Apigenin on chemotherapy-induced peripheral neuropathy (CIPN). METHODS: CIPN 
      mouse model was established using Paclitaxel treatment. Hot plate and tail prick 
      latency tests were performed to examine the allodynia and hyperalgesia behaviors. 
      Anti-inflammatory and anti-oxidative effects of Apigenin on CIPN were determined 
      by enzyme-linked immunosorbent (ELISA) assay, Western blot, and qRT-PCR. Nuclear 
      recruitment of nuclear factor erythroid 2-related factor 2 (NRF2) was analyzed to 
      evaluate the underlying mechanisms of the protective effects of Apigenin. 
      RESULTS: Apigenin significantly alleviated CIPN-induced nociceptive behaviors of 
      CIPN mice. It also decreased the TNF-alpha and IL-1beta levels, suppressed oxidative 
      stress and inflammation in the surgical spinal cord tissues. Mechanistically, 
      Apigenin altered the pro-inflammatory and anti-inflammatory phenotypes ratio of 
      microglia through promoting the nuclear recruitment of NRF2 and activating the 
      NRF2/Antioxidant Response Element (ARE) signaling pathway. CONCLUSIONS: In 
      summary, Apigenin relieves CIPN by regulating microglia activation and 
      polarization, which provides a potential therapeutic strategy for CIPN treatment.
CI  - (c) 2023 The Author(s). Published by IMR Press.
FAU - Xie, Wenji
AU  - Xie W
AD  - Department of Anesthesiology, Quanzhou First Hospital Affiliated to Fujian 
      Medical University, 362000 Quanzhou, Fujian, China.
FAU - Xie, Wenqin
AU  - Xie W
AD  - Department of Anesthesiology, Quanzhou First Hospital Affiliated to Fujian 
      Medical University, 362000 Quanzhou, Fujian, China.
FAU - Jiang, Changcheng
AU  - Jiang C
AD  - Department of Anesthesiology, Quanzhou First Hospital Affiliated to Fujian 
      Medical University, 362000 Quanzhou, Fujian, China.
FAU - Kang, Zhenming
AU  - Kang Z
AD  - Department of Anesthesiology, Quanzhou First Hospital Affiliated to Fujian 
      Medical University, 362000 Quanzhou, Fujian, China.
FAU - Liu, Naizhen
AU  - Liu N
AD  - Department of Anesthesiology, Quanzhou First Hospital Affiliated to Fujian 
      Medical University, 362000 Quanzhou, Fujian, China.
LA  - eng
GR  - 2020J011278/Fujian Natural Science Foundation/
PT  - Journal Article
PL  - Singapore
TA  - J Integr Neurosci
JT  - Journal of integrative neuroscience
JID - 101156357
RN  - 7V515PI7F6 (Apigenin)
RN  - 0 (NF-E2-Related Factor 2)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Mice
MH  - Animals
MH  - Hyperalgesia/chemically induced/drug therapy/metabolism
MH  - Apigenin/pharmacology/metabolism/therapeutic use
MH  - Microglia
MH  - NF-E2-Related Factor 2/metabolism
MH  - *Peripheral Nervous System Diseases/chemically induced/drug therapy
MH  - Anti-Inflammatory Agents/adverse effects
MH  - *Antineoplastic Agents/pharmacology
OTO - NOTNLM
OT  - Apigenin
OT  - CIPN
OT  - NRF2
OT  - inflammation
OT  - microglia
COIS- The authors declare no conflict of interest.
EDAT- 2023/06/01 01:08
MHDA- 2023/06/02 06:42
CRDT- 2023/05/31 22:22
PHST- 2022/08/21 00:00 [received]
PHST- 2022/09/22 00:00 [revised]
PHST- 2022/09/28 00:00 [accepted]
PHST- 2023/06/02 06:42 [medline]
PHST- 2023/06/01 01:08 [pubmed]
PHST- 2023/05/31 22:22 [entrez]
AID - S0219-6352(22)00462-4 [pii]
AID - 10.31083/j.jin2203064 [doi]
PST - ppublish
SO  - J Integr Neurosci. 2023 May 8;22(3):64. doi: 10.31083/j.jin2203064.